Free Trial

Manufacturing Stocks List

This page shows information about the 33 largest manufacturing sector stocks including Voyager Technologies, Cantaloupe, AIRO Group and Luda Technology Group. Learn more about manufacturing stocks.

1. Voyager Technologies NYSE:VOYG

$43.74 +0.70 (+1.63%)
As of 06/24/2025 03:58 PM Eastern

We are an innovation-driven defense technology and space solutions company. Our company was purpose-built to address issues at the forefront of defense, national security and space industries and we have organized our business to reflect this goal. We strive to solve complex challenges to fortify national security, protect critical assets and unlock new frontiers for human progress and economic development. We are committed to developing and delivering an array of transformative, mission-critical solutions to customers enabled by our advanced technology, analytics and space infrastructure capabilities. Our solutions include communications and intelligence collection systems, defense systems, advanced space technology, in-space infrastructure and space mission services. Our business consists of diversified solutions across three business segments: Defense & National Security, Space Solutions and Starlab Space Stations. Since 2019, we have accomplished significant achievements in each of these segments, including the successful deployment of first-of-its-kind missile defense maneuvering capabilities, the development of groundbreaking space technology and the selection by NASA to develop a replacement for the ISS. We operate a flexible business model that allows us to serve both as a “prime” contractor, providing fulsome and integrated solutions directly to customers, as well as a “merchant supplier,” or subcontractor, providing critical technologies to support several commercial and government programs across the space and national security sectors. Our key partners and customers include Palantir, NASA, Lockheed Martin, the U.S. Air Force and Sierra Space. Our ability to serve in both prime and merchant supplier capacities with these customers and partners allows us to selectively participate in a wide range of programs in whichever capacity is more attractive to us. Prime contractor roles allow us to lead the entirety of a program, managing the supply chain, technology integration and end customer relationship. Merchant Supplier roles are an opportunity for us to supply our differentiated technologies to a broader range of programs and support multiple prime competitors, on attractive terms. Our ability to serve in both capacities allows us to selectively participate in a wide range of programs in whichever capacity is best suited to our solution, financial contribution and probability of win. Our growth strategy includes organic and inorganic expansion, leveraging our existing technologies and pairing out our software capabilities with our hardware, leading to the development of new solutions to meet customer needs. Since 2019, we have executed and successfully vertically and horizontally integrated seven acquisitions, and have grown our revenue to $144.2 million in 2024 and $34.5 million for the three months ended March 31, 2025. In addition, we received cash proceeds of $3.0 million in 2022, $62.0 million in 2023, $62.2 million in 2024 and $20.0 million during the three months ended March 31, 2025 (with $70.3 million of eligible proceeds remaining as of March 31, 2025) from our $217.5 million development grant with NASA to design Starlab, the commercial space station replacement for the ISS which is set to be decommissioned in 2030. We intend to operate Starlab through Starlab JV, a Voyager-led and majority-owned global joint venture, with international equity partners that include Airbus, Mitsubishi, MDA Space and Palantir. Our growth and increased size and scale are the result of investment and focus on our key technology offerings, as well as our ability to attract, cultivate and integrate accretive acquisitions. Additionally, the threat environment is driving investment in solutions that cross multiple domains, such as missile defense programs that require interoperability among space-, air- and ground-based systems. Our position and technology heritage across multiple domains and systems positions us well to support this trend towards increasing convergence. Our business consists of diversified solutions across three business segments: • Defense & National Security, which provides innovative mission-critical solutions to protect dynamic and contested domains. We pioneer communications technologies, guidance, navigation and controls, signals intelligence and defense systems. • Space Solutions, which delivers space infrastructure, advanced space technology, science systems and mission services that power commercial, academic and government missions from low-Earth orbit to deep space. • Starlab Space Stations, which is a commercial space station planned to succeed the ISS and provide continued permanent human presence in space. It is operated through our U.S.-led global joint venture with Airbus, Mitsubishi, MDA Space and Palantir, among others. --- We operate in markets that have tailwinds supporting investment from both commercial and government clients worldwide. From a Defense & National Security perspective, we believe our solutions serve a total addressable market of $163 billion. Our serviceable addressable market is $11 billion. Our Space Solutions & Starlab Space Stations segments serve a total addressable market of $16 billion, of which we serve $1 billion. There are significant opportunities both in the U.S. as well as for allied international economics and governments. Our business thrives through collaboration and synergies across our various business segments. Our ability to share technology, identify cross-selling opportunities and realize cost savings through improved organizational efficiency drives our growth and financial performance. For example, we are developing artificial intelligence powered edge computing units to operate across Earth and space, layered with Palantir’s operating system and our end-to-end intelligence analytics platform, to deliver real-time intelligence capabilities for defense and national security applications and for space exploration. Starlab’s technical design and business case benefit tremendously from our broader organization, aiding in our continued development of the project. We are distinctively positioned as a leader in space science and commercialization and we intend to bring the extensive business development, mission design, management and customer service experience of our Space Solutions segment to support the development and operations of our Starlab Space Stations segment. We maintain long-term relationships with many of the industry’s largest and most important blue-chip customers, across both government agencies and commercial entities. Since our founding and through March 31, 2025, we have been awarded approximately $800 million in contracts and SAAs. Our largest customer is NASA, which represented 25.6% of our revenue for the year ended December 31, 2024 and 19.7% of our revenue for the three months ended March 31, 2025. Our close relationship with government customers highlights the public-private partnership model that has been a significant driver of growth in the national security and space industries and commercialization opportunities. For example, we attached the Bishop Airlock to the ISS in 2020, demonstrating the viability of the public-private partnership model for the development of critical commercial space infrastructure and paving the way for our partnership with NASA on Starlab. We expect this partnership model to continue to provide us with a significant opportunity to participate in critical national security and space technology development in the future. For example, in 2023, in addition to the $800 million in contracts and SAAs discussed above, we were awarded a $900 million ceiling IDIQ contract by the Air Force Life Cycle Management Center’s Architecture and Integration Directorate to deliver a cost-effective intelligence, surveillance and reconnaissance system. We believe we are well-positioned to benefit from this funding mechanism given our close relationships with government customers and our track record as a reliable technology and solutions provider. Although we see our relationship with the U.S. government as a positive, we do rely on this relationship for a substantial portion of our business. Changes to the U.S. government’s priorities and spending, or delays or reductions in spending, could have a material adverse effect on us. We benefit from business segments that serve varied end markets as well as meaningful customer diversity. We believe that our revenue diversification provides significant resiliency and positions us well to capitalize on new business opportunities across markets and customers. --- We also receive meaningful cash proceeds from our development grants for research and development, providing further diversity for financing our initiatives. Development grants allow us to receive sizeable funding from our customers to develop what we believe are next-generation technologies without having significant cash constraints due to our size. We also work hand-in-hand with our customers to create solutions addressing directly their needs. In December 2021, our subsidiary Nanoracks was awarded a SAA, which was subsequently transferred to us, and which we subsequently transferred to Starlab JV, under Phase I of NASA’s CDFF program as part of the agency’s effort to foster a commercial space station to succeed the ISS. Through this SAA, we were initially awarded $160 million in development grants—the largest CDFF award from NASA—to pursue the design and development of Starlab through 2026. In 2023, Northrop Grumman, another CDFF SAA recipient, withdrew its space station program and joined our effort as a strategic supply chain partner to Starlab. Subsequently, we were awarded an additional $58 million in development grants under our CDFF SAA, bringing our total grant to $217.5 million. As we achieve certain program milestones, cash proceeds are paid to us from the $217.5 million total grant, including $3.0 million paid in 2022, $62.0 million paid in 2023, $62.2 million paid in 2024, and $20.0 million paid in the three months ended March 31, 2025. As of March 31, 2025, we have $70.3 million of our development grant remaining. On January 13, 2025, we achieved the first milestone by successfully completing the preliminary design review in collaboration with NASA, an important step toward full-scale production. The next milestone is detailed design and hardware development, leading to a Critical Design Review to confirm Starlab’s readiness. The U.S. government continues to support investment in these technologies. For example, NASA’s fiscal year 2026 budget request includes approximately $2.1 billion for commercial LEO development through 2030. Based on our previous success receiving grants, we believe we are well-positioned to win future development grants and contracts from NASA and other space agencies to aid in funding the development of Starlab. Additionally, in 2025, we received an award of $15 million by the Texas Space Commission as part of their Space Exploration and Aeronautics Research Fund grant program to help support Starlab and grow its ecosystem of suppliers and customers across Texas. --- We are supported by a highly skilled workforce operating across our facility footprint. We believe our footprint is well-aligned with our markets, enabling close collaboration with government and commercial customers, reliable manufacturing operations and access to the required testing environment for our technologies. In addition to our footprint, our Starlab Space Stations segment benefits from access to the existing facilities and operations of our equity and strategic partners, lowering direct capital expenditure needs for Starlab development. These equity and strategic partners are also helping develop and deliver technologies, solutions and hardware for Starlab. Our principal executive offices are located in Denver, Colorado.

Market Capitalization
$2.42 billion
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
927,564 shares
Average Volume
5.32 million shares
Today's Range
$42.49
$45.44
50-Day Range
$0.00
$0.00
52-Week Range
$42.26
$73.95
Dividend Yield
N/A
Cantaloupe stock logo

2. Cantaloupe NASDAQ:USAT

$10.99 0.00 (0.00%)
As of 06/23/2025

Cantaloupe, Inc. is a software and payments company, which engages in the provision of end-to-end technology solutions for the unattended retail market. It offers Internet of Things (IoT) and machine-to-machine (M2M) services, which include the ability to remotely monitor, control, and report on the results of distributed assets containing the electronic payment solutions. The company was founded by George Raymond Jensen Jr. in January 1992 and is headquartered in Malvern, PA.

Market Capitalization
$781.16 million
P/E Ratio
-22.90
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
3.66 million shares
Average Volume
291,261 shares
Today's Range
$10.97
$11.02
50-Day Range
$7.39
$10.99
52-Week Range
$4.80
$12.94
Dividend Yield
N/A

3. AIRO Group NASDAQ:AIRO

$24.27 -2.63 (-9.78%)
As of 06/24/2025 04:00 PM Eastern

We are a technologically differentiated aerospace, autonomy, and air mobility platform targeting 21st century aerospace and defense opportunities. We leverage decades of industry expertise and connections across the drone, aviation, and avionics markets to provide leading solutions to the aerospace and defense market. We offer connected and diversified solutions providing operational synergies across our segments and are powered by an international footprint as well as supplier and public sector relationships. Supported by complementary and innovative technologies, we believe we bring a unique value proposition to the market and are well-positioned to become a differentiated leader in the industry. Our business is organized into four operating segments, each of which represents a critical growth vector in the aerospace and defense market: Drones, Avionics, Training, and Electric Air Mobility. These four segments collectively target a combined total addressable market estimated to be over $315.4 billion by 2030. --- Drones. The Drones segment develops, manufactures, and sells drones and will provide drone services, such as DaaS, for military and commercial end users. Our military drones are sold through our Sky-Watch brand, which is a key supplier to European NATO countries. A critical point of differentiation lies in our drones’ ability to perform in a GPS-denied environment, which is a technology application relevant for both military and commercial end markets. Avionics. The Avionics segment develops, manufactures, and sells avionics for military and general aviation aircraft, drones, and eVTOLs. Our advanced avionics products include flight displays, Connected Panels, and GPS/GNSS sensors, all of which have been installed on legacy military aircraft and general aviation platforms. We sell our advanced avionics through our Aspen Avionics brand, which is well-recognized in the general aviation aftermarket sector with over 20 years of operating history and long-term customer loyalty for our value proposition. We also serve as an avionics supplier for OEMs, including Robinson Helicopters, Pilatus, and Honeywell. We believe our avionics solutions have a considerable market opportunity as general aviation fleets continue to age, with owners and operators seeking to upgrade the avionics technology on their aircraft. Training. The Training segment currently provides military pilot training and will provide commercial pilot training in the future. We offer professional training and consulting services to the U.S. military, select NATO countries, and other U.S. allies under our CDI brand. These offerings include adversary air, close air support, ISR aircraft leasing, pilot training ground liaison services, and JTAC, as well as full joint theatre ISR and simulated ground strike training. We work closely with special military forces such as SEAL teams, the U.S. Naval Air Warfare Center, and USAF Air Combat Command, and are a mandated recipient on a $5.7 billion IDIQ contract. Our personnel’s top security clearances and established relationships at the Pentagon provide us with a differentiated ability to bid on mandates. We also plan to offer commercial pilot training and plan to expand our non-military capabilities in response to the global pilot shortage. Electric Air Mobility. The Electric Air Mobility segment is developing a rotorcraft eVTOL for cargo and passenger use through our Jaunt brand for fixed route flights, on-demand trips, and cargo operations. Our research and development (“R&D”) efforts are focused on developing a cargo eVTOL platform, which will be a scaled-down version of our passenger eVTOL platform, and will target the attractive middle mile delivery cargo market. Meanwhile, our long-term R&D efforts are focused on developing a full-scale multi-role eVTOL platform, which will be able to serve both the cargo and passenger markets. We plan to certify our eVTOLs through existing CAR 529 Rotorcraft standards, with our platform including the best attributes of both rotary and fixed wing aircraft. Our patented compound rotorcraft technology, a core point of technological differentiation that will underpin our cargo eVTOL’s commercial capability, has over 300 piloted flight hours on multiple Jaunt demonstrator aircraft. We believe the range and payload capabilities driven by this technology uniquely position us to provide a compelling commercial solution for the eVTOL cargo market. Once developed and certified, we expect our cargo eVTOL program will serve as the foundation of our commercialization efforts, with passenger applications serving as a longer-term secondary initiative. Our principal executive offices are located in Albuquerque, New Mexico.

Market Capitalization
$542.69 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
2.24 million shares
Average Volume
5.90 million shares
Today's Range
$23.50
$27.15
50-Day Range
$0.00
$0.00
52-Week Range
$12.90
$39.07
Dividend Yield
N/A
Luda Technology Group stock logo

4. Luda Technology Group NYSE:LUD

$6.09 0.00 (0.00%)
As of 06/24/2025 12:26 PM Eastern

We are a manufacturer and trader of stainless steel and carbon steel flanges and fittings products. Our history began with Luda HK which was incorporated in Hong Kong in 2004 and is principally engaged in the trading of steel flanges and fittings. In 2005, the Company’s business expanded further upstream when Luda PRC was set up to commence the manufacturing of flanges and fittings with self-owned factory in China. We have established an operation history of over 20 years. We are principally engaged in (i) the manufacture and sale of stainless steel and carbon steel flanges and fittings products; and (ii) trading of steel pipes, valves, and other steel tubing products. We are headquartered in Hong Kong with manufacturing base in Taian City, Shandong Province of the PRC. Our sales network comprises customers from China, South America, Australia, Europe, Asia (excluding China) and North America and our customers comprise manufacturers and traders from the chemical, petrochemical, maritime and manufacturing industries. Our principal office is located in Hung Hom, Kowloon, Hong Kong.

Market Capitalization
$138.18 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
29,524 shares
Average Volume
42,180 shares
Today's Range
$5.71
$6.21
50-Day Range
$3.79
$6.09
52-Week Range
$3.40
$8.00
Dividend Yield
N/A
FBR & Co. stock logo

5. FBR & Co. NASDAQ:FBRC

$17.55 0.00 (0.00%)
As of 06/12/2017

FBR & Co. is an investment banking and institutional brokerage company. The Company focuses on the equity capital markets. The Company operates through two segments: capital markets, which includes investment banking, institutional brokerage and research, and principal investing. Through its broker-dealer operating subsidiaries, the Company focuses its business on providing: capital raising services, including underwriting and placement of public and private equity, equity-linked and debt securities; financial advisory services, including merger and acquisition (M&A) advisory, restructuring, liability management, recapitalization and strategic alternative analysis; institutional sales and trading services focused on equities, equity-linked securities, listed options, high-yield bonds, senior debt and bank loans, as well as securities lending activities, and differentiated securities research.

Market Capitalization
$124.61 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
59,103 shares
Today's Range
$17.55
$17.55
50-Day Range
$17.55
$17.55
52-Week Range
$10.57
$19.53
Dividend Yield
4.52%
ESPEY MFG & ELECTRONICS stock logo

6. ESPEY MFG & ELECTRONICS NYSE:ESP

$41.22 +1.22 (+3.05%)
As of 06/24/2025 04:00 PM Eastern

Espey Mfg. & Electronics Corp., a power electronics design and original equipment manufacturing company, designs, manufactures, and tests electronic equipment primarily for use in military and industrial applications in the United States and internationally. The company's principal products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, antennas, and high-power radar systems for use in AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power applications. It also provides various services comprising design and development to specification, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment. In addition, the company produces individual components, such as inductors, printed circuit boards, wires, and tests items. It serves industrial manufacturers and defense companies, the government of the United States, foreign governments, and foreign electronic equipment companies through its direct sales organization and outside sales representatives. The company was incorporated in 1928 and is based in Saratoga Springs, New York.

Market Capitalization
$116.69 million
P/E Ratio
15.38
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
27,056 shares
Average Volume
18,672 shares
Today's Range
$39.18
$41.40
50-Day Range
$0.00
$0.00
52-Week Range
$20.50
$42.00
Dividend Yield
2.44%
Maxpro Capital Acquisition stock logo

7. Maxpro Capital Acquisition NASDAQ:JMAC

$5.70 -0.37 (-6.02%)
As of 06/20/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Market Capitalization
$76.47 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
3,746 shares
Average Volume
74,040 shares
Today's Range
$5.50
$6.00
50-Day Range
$4.89
$7.26
52-Week Range
$7.50
$19.22
Dividend Yield
N/A

8. Welsbach Technology Metals Acquisition NASDAQ:WTMA

$12.57 +0.57 (+4.77%)
As of 06/24/2025 02:21 PM Eastern

Welsbach Technology Metals Acquisition Corp. does not have significant operations. The company intends to effect a merger, stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on the technology metals and energy transition metals markets. Welsbach Technology Metals Acquisition Corp. was incorporated in 2021 and is based in Lombard, Illinois.

Market Capitalization
$37.84 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
1,849 shares
Average Volume
3,793 shares
Today's Range
$10.77
$12.57
50-Day Range
$11.41
$13.25
52-Week Range
$10.77
$13.50
Dividend Yield
N/A

9. Mana Capital Acquisition NASDAQ:MAAQ

$3.70 -0.01 (-0.27%)
As of 06/23/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Market Capitalization
$30.06 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
17,060 shares
Average Volume
33,075 shares
Today's Range
$3.62
$3.73
50-Day Range
$0.19
$5.35
52-Week Range
$5.35
$10.25
Dividend Yield
N/A
OSR stock logo

10. OSR NASDAQ:OSRH

$1.28 -0.03 (-2.29%)
As of 06/24/2025 04:00 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Market Capitalization
$25.25 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
204,244 shares
Average Volume
107,726 shares
Today's Range
$1.25
$1.50
50-Day Range
$1.11
$1.67
52-Week Range
$1.02
$13.40
Dividend Yield
N/A
Linkers Industries stock logo

11. Linkers Industries NASDAQ:LNKS

$0.56 -0.01 (-2.09%)
As of 06/24/2025 04:00 PM Eastern

Linkers Industries Ltd. is a holding company, which engages in the business of manufacturing, supplying, and selling connectors, assemblies, wire, and cable harnesses. It operates through the following geographical segments: Thailand, Malaysia, Switzerland, the United States of America, and Others. The company was founded on December 8, 2022 and is headquartered in Sungai Petani, Malaysia.

Market Capitalization
$6.33 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
294,313 shares
Average Volume
158,104 shares
Today's Range
$0.53
$0.63
50-Day Range
$0.52
$0.67
52-Week Range
$0.45
$10.27
Dividend Yield
N/A
Bellevue Life Sciences Acquisition stock logo

12. Bellevue Life Sciences Acquisition NASDAQ:BLAC

$1.31 -0.23 (-14.94%)
As of 06/23/2025

Bellevue Life Sciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC.

Market Capitalization
$5.29 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
216,326 shares
Average Volume
21,069 shares
Today's Range
$1.22
$1.71
50-Day Range
$1.11
$1.67
52-Week Range
$3.01
$13.40
Dividend Yield
N/A
Palatin Technologies stock logo

13. Palatin Technologies NYSE:PTN

$0.09 -0.08 (-44.65%)
As of 05/7/2025

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Market Capitalization
$2.45 million
P/E Ratio
-0.06
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
14.57 million shares
Average Volume
2.28 million shares
Today's Range
$0.09
$0.11
50-Day Range
$0.09
$0.23
52-Week Range
$0.09
$2.48
Dividend Yield
N/A
PowerUp Acquisition stock logo

14. PowerUp Acquisition NASDAQ:PWUP

$0.28 -0.01 (-2.79%)
As of 06/23/2025

PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.

Market Capitalization
$2.19 million
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
614,324 shares
Average Volume
3,153 shares
Today's Range
$0.27
$0.29
50-Day Range
$0.22
$0.71
52-Week Range
$8.05
$15.80
Dividend Yield
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
N/A
Today's Range
$0.00
$0.00
50-Day Range
$0.00
$0.00
52-Week Range
$0.00
$0.00
Dividend Yield
N/A
Welsbach Technology Metals Acquisition stock logo

16. Welsbach Technology Metals Acquisition NASDAQ:WTMAR

$0.45 -0.05 (-10.00%)
As of 06/24/2025 01:45 PM Eastern

Welsbach Technology Metals Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on the technology metals and energy transition metals sectors. Welsbach Technology Metals Acquisition Corp. was incorporated in 2021 and is based in Lombard, Illinois.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
5,500 shares
Average Volume
21,876 shares
Today's Range
$0.45
$0.48
50-Day Range
$0.16
$0.50
52-Week Range
$0.06
$0.55
Dividend Yield
N/A

17. TradeUP Acquisition NASDAQ:UPTDW

$0.04 +0.00 (+2.56%)
As of 06/23/2025

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
127,620 shares
Average Volume
21,379 shares
Today's Range
$0.04
$0.04
50-Day Range
$0.04
$0.09
52-Week Range
$0.02
$0.40
Dividend Yield
N/A
Palladyne AI stock logo

18. Palladyne AI NASDAQ:STRCW

$0.40 -0.03 (-5.93%)
As of 06/23/2025

Palladyne AI Corp., a software company, focuses on delivering software that enhances the utility and functionality of third-party stationary and mobile robotic systems in the United States. Its Artificial Intelligence (AI)/ Machine Learning (ML) software platform enables robots to observe, learn, reason, and act in structured and unstructured environments. The company's software platform enables robotic systems to perceive their environment and quickly adapt to changing circumstances by generalizing from their experience using dynamic real-time operations without extensive programming and with minimal robot training. It serves customers from various industries, such as industrial manufacturing, warehousing and logistics, defense, infrastructure maintenance and repair, energy, aerospace and aviation, and others. The company was formerly known as Sarcos Technology and Robotics Corporation and changed its name to Palladyne AI Corp. in March 2024. Palladyne AI Corp. was founded in 2017 and is headquartered in Salt Lake City, Utah.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
40,170 shares
Average Volume
56,080 shares
Today's Range
$0.39
$0.44
50-Day Range
$0.19
$0.53
52-Week Range
$0.00
$0.24
Dividend Yield
N/A

19. Rosecliff Acquisition Corp I NASDAQ:RCLFW

$0.54 -0.02 (-3.71%)
As of 06/20/2025

Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
3,849 shares
Average Volume
46,234 shares
Today's Range
$0.50
$0.58
50-Day Range
$0.29
$0.59
52-Week Range
$0.00
$0.27
Dividend Yield
N/A

20. Psyence Biomedical NASDAQ:PBMWW

$0.02 +0.00 (+0.46%)
As of 06/24/2025 03:31 PM Eastern

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
117,928 shares
Average Volume
50,270 shares
Today's Range
$0.02
$0.02
50-Day Range
$0.01
$0.02
52-Week Range
$0.00
$0.05
Dividend Yield
N/A

21. NorthView Acquisition NASDAQ:NVACR

$0.19 -0.01 (-4.04%)
As of 06/24/2025 02:28 PM Eastern

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation operates as a subsidiary of NorthView Sponsor I, LLC.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
89,100 shares
Average Volume
94,008 shares
Today's Range
$0.15
$0.19
50-Day Range
$0.10
$0.20
52-Week Range
$0.01
$0.23
Dividend Yield
N/A
Neonc Technologies stock logo

22. Neonc Technologies NASDAQ:NTHI

$3.70 -0.78 (-17.41%)
As of 06/24/2025 04:00 PM Eastern

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
46,960 shares
Average Volume
64,099 shares
Today's Range
$3.51
$4.31
50-Day Range
$3.70
$7.49
52-Week Range
$3.51
$25.00
Dividend Yield
N/A

23. G Medical Innovations NASDAQ:GMVDW

G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
5,762 shares
Today's Range
$0.00
$0.00
50-Day Range
$0.02
$6.90
52-Week Range
$0.13
$9.00
Dividend Yield
N/A

24. Fidelity Select Wireless NASDAQ:FWRLX

$11.86 +0.10 (+0.85%)
As of 06/23/2025

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
N/A
Today's Range
$11.86
$11.86
50-Day Range
$11.13
$11.86
52-Week Range
$0.00
$0.00
Dividend Yield
N/A

25. 4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
20,931 shares
Today's Range
$0.00
$0.00
50-Day Range
$0.00
$0.00
52-Week Range
$0.04
$1.29
Dividend Yield
N/A
Jupiter Wellness stock logo

26. Jupiter Wellness NASDAQ:JUPWW

$0.03 +0.01 (+83.04%)
As of 06/23/2025

jupiter wellness, inc. operates as a hemp-derived cannabidiol (cbd) consumer product development company. it develops various therapeutic and medical use for cbd in the treatment of various ailment and diseases, such as cancer, arthritis, anxiety, insomnia, psoriasis, chronic pain, and others. the company markets cbd-infused sun care lotion formulas containing various sun protection factors under the canisun brand. it is also developing other products, such as cbd-infused skin care lotion under the caniskin brand; and dermatological treatments under the canidermrx brand. the company was formerly known as cbd brands, inc. jupiter wellness, inc. was founded in 2018 and is headquartered in jupiter, florida.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
14,247 shares
Average Volume
6,964 shares
Today's Range
$0.02
$0.04
50-Day Range
$0.02
$0.15
52-Week Range
$0.02
$2.00
Dividend Yield
N/A
Electric Last Mile Solutions, I stock logo

27. Electric Last Mile Solutions, I NASDAQ:ELMSW

Electric Last Mile Solutions, Inc., a commercial electric vehicle solutions company, focuses on designing, engineering, manufacturing, and customizing electric ‘last mile' delivery and utility vehicles. It offers Class 1 commercial electric vehicle in the U.S. market and focuses on producing Class 3 Urban Utility electric vehicle. The company is headquartered in Troy, Michigan.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
75,897 shares
Today's Range
$0.00
$0.00
50-Day Range
$0.00
$0.00
52-Week Range
$0.00
$2.97
Dividend Yield
N/A

28. Cortigent NASDAQ:CRGT

Cortigent, through its predecessor Second Sight Medical Products, Inc., is a pioneer in developing precision (targeted) neurostimulation systems to help patients recover critical body functions. Our technology combines advanced neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Our first commercial system, Argus II®, a retinal implant, was approved by the U.S. Food and Drug Administration (“FDA”) under a Humanitarian Device Exemption (“HDE”) and has provided artificial vision to hundreds of profoundly blind people who were implanted with this device. Building on this neurostimulation platform we have completed an early feasibility clinical trial to evaluate a more advanced system for artificial vision that we call “Orion.” We are further exploring the application of our Orion® neurostimulation technology for accelerating the recovery of arm and hand function in patients who are partially paralyzed due to stroke. In February 2023, we held a meeting with FDA staff to commence discussions of an early feasibility clinical study in stroke victims. We believe that additional future applications of our platform technology may have the potential to generate substantial business growth over time. Both the Argus II and Orion devices create artificial vision by using electrical stimulation. Artificial vision does not restore normal stereoscopic vision or vision with color but rather perceptions of light and shapes requiring implantees to interpret their environment through specialized training. This artificial vision can aid in supporting basic tasks such as finding a doorway, detecting another person’s presence, following a sidewalk or locating an object. For the Argus II device, the stimulation is delivered to the surviving cells of the retina which convey the activity to the brain via the optic nerve. For the Orion device, electrical stimulation is delivered directly to the visual cortex, the region of the brain responsible for vision. The pattern of electrical stimulation corresponds to the images captured by a small video camera mounted in the center of the glasses that the patient wears and is connected to the video processing unit (“VPU”). The VPU is a battery-powered device worn by the user, typically on a belt or a strap, that sends power and stimulation commands to the implant and receives diagnostic information from the implant via the external antenna of the glasses. Argus II users undergo surgery to implant an electrode array inside the eye on the surface of the retina and affix a small electronics case (like a metal button) and an antenna to the outer surface of the eye. A small cable traverses the eye wall, connecting the electronics case to the array. Orion users undergo cranial surgery to implant an electrode array placed on the surface of the brain on the visual cortex and have a small electronics case and an antenna implanted on the outside of the skull, but completely covered by the scalp. A small cable passes through the skull to connect the array to the electronics case. No part of the device penetrates or cuts into the brain tissue itself. The quality of the artificial vision created by both the Argus II and Orion systems varies from patient to patient. The perception typically appears as a collection of up to 60 small points of light that correspond to the brightness of the different regions of the visual image detected by a camera. With scanning and repetition, patients can use their perception of the lights to construct a better understanding of their environment. The Argus II design process began in 2004. The Argus II was a novel device that required the components to be developed internally. The Argus II feasibility study commenced in 2006. In March 2011, the Argus II® Retinal Prosthesis System was approved for commercial use in the European Union to provide visual perception in patients with profound blindness due to retinitis pigmentosa (“RP”), a rare condition. The device was initially available in the United Kingdom, France, Germany and several other countries at a price of approximately USD $115,000. In February 2013, the U.S. Food and Drug Administration (FDA) approved Argus II under a Humanitarian Device Exemption, and in August 2013 the reimbursement price for Medicare patients was approved at approximately $150,000. More than 350 profoundly blind people around the world have received Argus II retinal implants. Many of these patients have been using their Argus implants for more than ten years, confirming our high manufacturing standards and product reliability. The market opportunity for the Argus II was limited to the small number of patients who have profound blindness due to RP, and we discontinued production and marketing of the Argus system in 2019 due to resulting commercial considerations. To make artificial vision available to a much larger group of individuals who are blind due to a wider range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury, we designed and built our next generation system, the Orion® Visual Cortical Prosthesis System (“Orion”). The Orion system leverages our 20 years of experience in precision neurostimulation for artificial vision. To be eligible for the Orion system, patients must be bilaterally blind with bare or no light perception. This is defined as non-measurable binocular visual acuity, or 5° or less visual field in each eye. We refer to these eligibility criteria as “profound blindness.” Cranial surgery is required to place the electrode array onto the brain’s surface; the Orion system has been designed not to penetrate the brain tissue. The design process began in 2014 and required substantial changes to the Argus II implant electronics to generate higher currents with a redesigned array for implantation on the brain cortex rather than within the eye. In November 2017 we commenced an Early Feasibility Study (EFS) of Orion in six patients who enrolled at two medical sites, the Ronald Reagan UCLA Medical Center in Los Angeles (“UCLA”) and the Baylor College of Medicine in Houston (“Baylor”). Regularly scheduled visits at both sites were paused in mid-March 2020 due to the COVID-19 outbreak; visits at UCLA resumed in September 2020 and at Baylor in December 2020. Three of the six patients were explanted after the third year of the study and the remaining three patients continue to use their devices outside of the clinic. We have three-year safety data for all six subjects, and five-year safety data for three subjects: . Orion safety data: Five subjects experienced a total of seventeen adverse events (AEs) and one subject did not report any adverse events related to the device or to surgery through July 2024. One was considered a serious adverse event (SAE) and all other adverse events were not serious. The single SAE, a seizure, occurred about three months post-implant, was resolved safely and quickly, and did not require a hospital stay. The investigators determined that this SAE was device-related and not unexpected as it had been disclosed as a potential safety risk in the patient informed consent form. The SAE occurred as we attempted to explore the optimal treatment frequency, which is a key stimulation parameter. The SAE occurred at a specific frequency. All adverse events are evaluated by an independent medical safety monitoring (IMSM) committee. With the IMSM committee’s input, we thereafter kept stimulation frequencies for all patients below the level that induced the SAE, and we have not observed any other seizures in this or any other participant. The FDA requires medical device manufacturers to follow 21 CFR 820 and maintain a Quality Management System (QMS). As a part of our QMS, we conform to ISO 14971, an FDA-recognized standard, to identify the hazards associated with the medical device, to estimate and evaluate the associated risks, to control these risks, and to monitor the effectiveness of the controls. There have been no serious adverse events due to the device or surgery since June 2018. One patient chose to have the device explanted before the 36th month due to an unrelated medical condition. Two other patients subsequently requested explantation for reasons unrelated to the device’s efficacy or safety. Cortigent’s independent medical safety monitor (IMSM) has determined that the reasons for these explants were not related to the device or the surgery. We have three-year efficacy data for five of the six original subjects (one did not participate in this assessment), and five-year efficacy data for three subjects: . Orion efficacy data: We assess efficacy by looking at three measures of visual function: 1) Square localization – Orion subjects sit in front of a touch screen and are asked to touch within the boundaries of a square when it appears; 2) Direction of motion – Subjects are asked to identify the direction of the motion of a line that traverses a screen; and 3) Grating visual acuity – a measure of visual acuity that is adapted for very low vision. Five of the six original subjects completed the planned efficacy assessments at 36 months post-implant and three completed these assessments at 60 months. – For square localization, at 36 months five of the six original subjects remained in the study and all performed significantly better with the system turned on versus turned off. At 60 months, three of the six original subjects remained in the study and all performed significantly better. – For direction of motion, at 36 months the five subjects remaining in the study all performed significantly better with the system turned on than with it turned off. At 60 months, the three subjects remaining in the study all performed significantly better. – For grating visual acuity, at 36 months two of the five subjects remaining in the study had measurable visual acuity with the system turned on compared to none with the device turned off. At 60 months, two of three remaining subjects had measurable visual acuity. Another efficacy measurement of day-to-day functionality and benefit is the Functional Low-Vision Observer Rated Assessment (FLORA). The FLORA assessments were performed by an independent, third-party specialist who spent time with the subjects in their homes. The specialist asked each subject a series of questions and observed them performing 15 or more daily living tasks with the Orion system turned on and with it turned off, such as finding light sources, following a sidewalk, or sorting laundry. The specialist then determined if the system was providing a benefit, was neutral, or impaired the subject’s ability to perform these tasks. Four of four subjects who completed the FLORA evaluation at 36 months had positive or mildly positive results indicating that the Orion system was providing benefit. This evaluation was not performed at the 60-month timepoint. Cortigent is planning to work with the FDA to gain agreement on the additional clinical studies that will be required to secure marketing approval for Orion. The FDA categorizes electronic medical devices that are implanted as Class III. Both the Argus II and Orion are in this Class III category and require FDA approval. Class III devices face higher burdens to attain regulatory approval; Cortigent (formerly Second Sight Medical) successfully navigated this approval process with the Argus II system. The Argus II clinical trial enrolled patients with late-stage retinitis pigmentosa, a rare disease, affecting less than four thousand Americans. This small potential market size of fewer than 8,000 individuals enabled the Argus II to qualify for a Humanitarian Device Exemption (HDE) which the FDA granted in February 2013. In November 2017, the FDA granted an Expedited Access Pathway (EAP) designation to the Orion system to treat individuals who are bilaterally blind due to non-cortical etiology and who are not candidates for any other commercially approved vision restoration therapy. The Breakthrough Device Program (BDP) subsumed the EAP program and its devices in December 2018. Breakthrough Device designations, such as granted to Orion, are intended to accelerate medical device development, assessment, and review, while preserving the statutory standards for premarket approval. The potential patient population for Orion is expected to include blindness due to most common causes, including glaucoma, diabetic retinopathy, eye trauma, optic nerve damage, and retinitis pigmentosa. According to a company-sponsored 2018 study by Fletcher Spaght Inc., there are about 82,000 Americans who could potentially benefit from the Orion system. We are developing a platform technology with multiple potential applications: Our current-generation miniature neurostimulation device with 60 independently controlled cortical stimulation channels, supported by reliability data from the Argus II and Orion programs, is expected to serve as a platform for targeting other conditions with high unmet medical need. Technical evaluations of potential new indications for the technology began in 2021. We believe that our most promising next target will be to apply cortical neurostimulation to improve recovery of arm and hand function in partially paralyzed stroke patients who are undergoing rehabilitation after stroke. This medical treatment concept is supported by evidence from clinical studies conducted by Northstar Neuroscience, Inc. in the early 2000s using a single-channel electrical stimulation device that was placed on the motor cortex, the area of the brain surface that controls hand and arm motion (the same surface area of the brain where our device will be placed). Northstar reported achieving positive patient results in its Phase 1 and Phase 2 clinical studies (Cramer 2007) but a pivotal Phase 3 study failed to achieve statistical significance at the 4-week primary endpoint. Northstar was unable to obtain FDA approval and was eventually dissolved. It has been reported that a clinical benefit was demonstrated at six months (Levy 2016). We believe that our 60-channel cortical stimulation device has the potential to target neuron bundles more precisely and generate favorable clinical results. Like Orion, the stroke recovery system will require cranial surgery; in this case to place the electrode array on the motor cortex. We began to design the stroke system in 2022, and during February 2023 we studied what we believe to be the optimal array placement on the motor cortex of a cadaver. We have filed an NIH grant application to seek non-dilutive funding to support this program but it was not initially awarded. We plan to reapply for grant funding in early 2025. In addition, in February 2023 we held a pre-submission (“Pre-Sub”) meeting with FDA staff to discuss commencing an Early Feasibility Study of the stroke recovery system. We applied for a Breakthrough Device designation for the stroke recovery system in April 2023 and the FDA responded that human clinical data will be needed to make this determination. If we fail to secure this designation, we may experience slower interactions with the FDA that could delay our projected development timelines. We are targeting substantial revenue opportunities: The Orion system, designed to provide visual perception to profoundly blind people, has a target market of approximately 82,000 individuals in the U.S., assuming the planned indication is achieved (profound blindness due to glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury), based on a study by an independent market research firm engaged by Cortigent. We believe that about one-third of these patients could be reached by a marketing program. Depending on study results to assess clinical utility, Cortigent may seek reimbursement similar to or higher than the $150,000 per device that was approved by the Centers for Medicare and Medicaid Services (“CMS”) for the Argus II system. These assumptions translate into an estimated total addressable U.S. market size that could potentially exceed $4 billion at the time of launch. We believe that there are substantially more blind people who could potentially benefit from Orion in Europe, Asia and other world areas. There are approximately 7.6 million living Americans who have reported a stroke in their lifetime. (Tsao 2022). Consequently, we believe that the sales potential for a medical device system that can help improve motoric function in partially paralyzed stroke victims is very large. Each year approximately 610,000 Americans have a first stroke (Kissela 2012). Among the over 80% of people who survive a first stroke, the most common neurological deficit is motor weakness on one side of the body (hemiparesis), and approximately 40% of these stroke victims suffer moderate to severe motor impairment that requires special care (Gresham 1995). If our device achieves treatment success, as to which we can make no assurance, we estimate that it could potentially benefit up to 195,000 U.S. stroke victims each year, creating a total addressable market estimated at approximately $6 billion by the time of system launch. Several critical development and regulatory milestones must be accomplished in order to complete and market the Orion and stroke recovery systems. We face the material risks of failing to achieve successful clinical trials, to attain regulatory approvals, and to secure favorable product reimbursement for patients covered by Medicare and other types of insurance. Even with a successful trial, it could be determined that certain patient subpopulations cannot be effectively treated by our devices which would reduce our product sales potential. The development process may take longer and be more costly than anticipated and we may not achieve reimbursement levels similar to the one we received for our Argus II device or obtain other suitable reimbursement levels that we may require. Since we currently have no commercial revenues, any of these outcomes could require substantial additional funding. No assurance can be made that clinical trials will demonstrate safety and efficacy or will lead to commercial products. Clinical trial planning: The five-year Orion Early Feasibility Study was completed in July 2023, and at our election is being extended by approximately another year to allow for additional exploratory research to improve vision quality, for example by enhanced contrast filtering or by other software modifications. The next step will be to manufacture and validate new Orion devices for a planned pivotal clinical trial that we expect will involve approximately 60 profoundly blind subjects at approximately 10 U.S. trial centers. These are internal estimates and the size of the Orion pivotal clinical trial will depend upon further review and collaborations with the FDA. Our intended target is to commence the pivotal trial by or about mid 2026, complete it by approximately mid 2028, and if successful to obtain FDA clearance and launch Orion on the US market in early 2029. For the stroke recovery system, we anticipate manufacturing modified clinical trial devices for the planned Early Feasibility Study (EFS) in parallel with manufacturing of the Orion devices. Our intended target is to commence this EFS for the stroke recovery system in mid 2026. We anticipate a shorter time for stroke recovery patients to reach the primary study endpoint than for Orion (nine months versus 12 months, respectively). Patient population size and other terms of the stroke recovery system pivotal trial will depend upon the outcomes of the stroke recovery systems EFS and on further review and collaboration with the FDA. Our intended target is to commence a pivotal clinical trial for the stroke recovery system in late-2027, complete it by mid 2029, and if successful to be able to launch the stroke recovery system in late 2029. The target clinical development timelines for Orion and the stroke recovery system, shown in the diagram below, are subject to further discussions and collaborations with the FDA and assume that adequate financing will be available to fund the execution of our clinical development programs. Clinical trials require FDA approvals and clearances. No assurance can be given that we will be able to obtain these approvals and clearances, that we will obtain approval of a marketable device or that we will be able to launch commercially successful products. --- The timeline presented represents management’s estimate of the time required to complete each stage. No assurance can be given that these timelines will prove correct. Intellectual property: Cortigent has amassed an extensive intellectual property estate consisting of rights (as of September 30, 2024) to 207 issued U.S. patents, 20 issued European patents (nationalized in France and Germany, or a unitary patent plus Great Britain), two pending U.S. patent applications, including a recent filing covering the stroke recovery device under development, two pending European patent applications, four issued U.S. design patents and four issued European design registrations (with six corresponding issued British design registrations). Our patent estate covers the technologies invented during the development of the Argus and Orion devices. Our patent estate primarily covers the core technologies of implant neurostimulation techniques and achieving implant longevity, which are integral to our current and future product lines, including the planned stroke rehabilitation system. Pre-Revenue company: We are a pre-revenue company with a history extending from 1998, including the history of our predecessor Second Sight Medical Products, Inc., of recurring operating losses that are likely to continue for the foreseeable future. We will require substantial additional capital, including the proceeds of this offering, to continue development of our products and fund clinical trials. Relationship with Vivani Prior to this offering Cortigent has been a wholly owned subsidiary of Vivani Medical, Inc. (Nasdaq: VANI), formerly known as Second Sight Medical Products, Inc. (“Second Sight”). Second Sight had historically operated as a standalone public company but completed a merger with Nano Precision Medical, Inc. as of August 2022. Vivani Medical, Inc. is the resulting entity of this August 2022 merger of Nano Precision Medical Inc. into a subsidiary of Second Sight Medical Products, Inc. Cortigent includes personnel, technologies, intellectual property and other assets that formerly comprised the vision operations of Second Sight Medical Products, Inc. Cortigent was organized as a Delaware corporation in November 2022 as a successor to the business and operations formerly conducted by Second Sight Medical Products, Inc. Our principal executive offices are located in 27200 Tourney Road, Suite 315 Valencia, California.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
N/A
Today's Range
$0.00
$0.00
50-Day Range
$0.00
$0.00
52-Week Range
$0.00
$0.00
Dividend Yield
N/A

29. Captivision NASDAQ:CAPTW

$0.03 0.00 (-13.33%)
As of 06/24/2025 03:29 PM Eastern

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
43,972 shares
Average Volume
67,900 shares
Today's Range
$0.02
$0.03
50-Day Range
$0.01
$0.04
52-Week Range
$0.01
$0.09
Dividend Yield
N/A
biote stock logo

30. biote NASDAQ:BTMDW

$0.02 0.00 (-10.18%)
As of 06/23/2025

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
27,338 shares
Average Volume
58,814 shares
Today's Range
$0.01
$0.02
50-Day Range
$0.01
$0.03
52-Week Range
$0.05
$1.68
Dividend Yield
N/A
Belive stock logo

31. Belive NASDAQ:BLIV

$3.78 +0.07 (+1.89%)
As of 06/24/2025 04:00 PM Eastern

BeLive Holdings engages in the development of software and programming activities and provides consultancy services. The company offers technology solutions for live commerce and shoppable short videos. It offers services through BeLive White Label solution and a cloud-based BeLive software-as-a-service (SaaS) solution. The company was founded on June 18, 2014 and is headquartered in Singapore.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
26,978 shares
Average Volume
217,033 shares
Today's Range
$3.55
$3.84
50-Day Range
$3.04
$5.05
52-Week Range
$2.69
$6.40
Dividend Yield
N/A
Anzu Special Acquisition Corp I stock logo

32. Anzu Special Acquisition Corp I NASDAQ:ANZUW

$0.04 +0.01 (+16.44%)
As of 06/20/2025

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices, such as auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
740 shares
Average Volume
32,101 shares
Today's Range
$0.04
$0.04
50-Day Range
$0.03
$0.07
52-Week Range
$0.00
$0.15
Dividend Yield
N/A

33. Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.01 0.00 (0.00%)
As of 06/23/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

Market Capitalization
N/A
P/E Ratio
N/A
Consensus Rating
N/A
Consensus Price Target
N/A
Volume
N/A
Average Volume
34,287 shares
Today's Range
$0.01
$0.01
50-Day Range
$0.00
$0.03
52-Week Range
$0.06
$0.33
Dividend Yield
N/A